{
    "id": 29333,
    "fullName": "SMO W281L",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SMO W281L lies within the ligand-binding pocket of the Smo protein (PMID: 25759020). W281L has been identified in the scientific literature (PMID: 25199678), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed Apr 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                },
                {
                    "id": 14067,
                    "pubMedId": 25199678,
                    "title": "Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25199678"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "W281L",
    "createDate": "02/12/2019",
    "updateDate": "04/02/2020",
    "referenceTranscriptCoordinates": {
        "id": 178556,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129205704G>T",
        "cDna": "c.842G>T",
        "protein": "p.W281L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15947,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a de novo SMO W281L mutation was identified in a recurrent lesion from a basal cell carcinoma patient following an initial twenty week response to Erivedge (vismodegib) (PMID: 25199678).",
            "molecularProfile": {
                "id": 31334,
                "profileName": "SMO W281L"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14067,
                    "pubMedId": 25199678,
                    "title": "Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25199678"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31334,
            "profileName": "SMO W281L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178556,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129205704G>T",
            "cDna": "c.842G>T",
            "protein": "p.W281L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}